Second dose of IV immunoglobulin ‘might be harmful’ in Guillain-Barre syndrome
The first randomised controlled trial testing efficacy found no benefit and an increased risk of thromboembolic events
Giving patients with severe Guillain-Barre syndrome a repeat dose of intravenous immunoglobulin is unlikely to provide a clinical benefit and may do harm, Dutch researchers say.
Their randomised controlled trial in 59 hospitals in the Netherlands between 2010 and 2018 is the first to examine the efficacy and safety of giving a second dose of intravenous immunoglobulin (IVIg).
